Ignite Creation Date:
2024-10-25 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06612697
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-09-22
Brief Title:
Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Nasopharyngeal carcinoma NPC is a malignant tumor primarily originating in the nasopharynx commonly found in populations in southern China certain regions of Asia and North Africa The main treatment for NPC is primarily radiotherapy with some patients receiving combined chemotherapy Early-stage NPC patients can achieve adequate tumor control with radiation therapy alone Various studies report that the 5-year survival rate for very early-stage NPC exceeds 90 However some stage I patients experience local recurrence or distant metastasis after treatment indicating treatment failure This study aims to retrospectively analyze the factors contributing to treatment failure and prognostic factors in this group of early-stage NPC patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None